CVS will remove Humira from its commercial formularies in favor of covering the immunosuppressive drug’s biosimilars starting April 1, the major retail pharmacy chain announced in a statement Wednesday (Jan. 3). The move comes after Humira manufacturer AbbVie prevented biosimilars from gaining market share, and as lawmakers are attempting to increase biosimilar uptake through drug-pricing and pharmacy benefit manager (PBM) reforms. CVS says in a news release the decision will potentially lower costs for its customers by more than 50%...